Connect Biopharma Holdings (CNTB) reported positive topline preliminary results for its Phase 1 clinical pharmacology study evaluating intravenous rademikibart, the next-generation, anti-interleukin-4-receptor alpha antibody. Rademikibart 300 mg administered by 2-minute IV push produced substantially faster improvement in FEV1 than what was previously observed with 600 mg subcutaneous administration, with clinically important increases of 100 mL - >400mL observed in many asthma and COPD patients as early as 15 minutes post-dosing. Mean FEV1 improvements from baseline of approximately 200 - 400 mL in patients receiving rademikibart were generally maintained through Day 29 in both asthma and COPD patients.
The company expects to report topline data from both ongoing Phase 2 Seabreeze STAT studies of rademikibart for acute exacerbations in asthma and COPD in mid-2026 and plans to move quickly to meet with the FDA to gain alignment on a Phase 3 program.
In pre-market trading on NasdaqGM, shares of Connect are up 11.27% to $3.83.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.